FindTrial
Sign In

Value of Immunomodulator drug(probiotics) in lung function of Bronchial Asthma subjects

Evaluation of role of add on probiotics on impact of lung function and bronchial asthma control - A randomized control trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/032105
Enrollment
84
Registered
2021-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

Intervention1: Standard treatment for Bronchial asthma as per GINA guidelines (LABA - Salmeterol,Formoterol ect with ICS-Budesonide etc) combined with probiotic: Add on therapy of probiotic (Lactobaci

Sponsors

Boopathi S
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All adult stable asthma with or without atopy and allergic rhinitis Both genders

Exclusion criteria

Exclusion criteria: Acute Respiratory infection including Tuberculosis Exacerbation Subjects contraindicated and unable to perform spirometry Underlying respiratory disorders

Design outcomes

Primary

MeasureTime frame
To evaluate the role of add on probiotics on impact of lung function by spirometry and bronchial asthma controlTimepoint: Baseline,4 weeks,8 weeks and 12 weeks—

Secondary

MeasureTime frame
To study the impact of probiotics supplementation in risk of asthma exacerbation allergic rhinitis and its impact on asthma scoringTimepoint: 3 months—

Countries

India

Contacts

Public ContactBoopathi S

Chetinad Academy of Research and Education

paddy_2020@yahoo.com9840245981

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026